FdaApplication
BLA 125806
Identifiers
- fda_app_no: BLA125806
Properties
| Property | Value |
|---|---|
| applicant_name | Rocket Pharmaceuticals Inc |
| application_type | BLA |
| approval_date | 2026-03-26 |
Revenue by product
KRESLADI
| Period | Revenue |
|---|---|
| Q2 2026 | $0.0M† |
| Q1 2026 | $0.0M† |
| Q4 2025 | $0.0M† |
| Q3 2025 | $0.0M† |
| Q2 2025 | $0.0M† |
| Q1 2025 | $0.0M† |
| Q4 2024 | $0.0M† |
| Q3 2024 | $0.0M† |
| Q2 2024 | $0.0M† |
| Q1 2024 | $0.0M† |
| Q4 2023 | $0.0M† |
| Q3 2023 | $0.0M† |
| Q2 2023 | $0.0M† |
| Q1 2023 | $0.0M† |
| Q4 2022 | $0.0M† |
| Q3 2022 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| KRESLADI | — | 0.34 to 6.1 10^6 cells/mL (including 0.32 to 6.1 10^6 CD34+ cells/mL) | Suspension |
1 product